within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05C_CapillaryStabilizingAgents.C05CA53_DiosminCombinations;

model DiosminCombinations
  extends Pharmacolibrary.Drugs.ATC.C.C05CA53;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C05CA53</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Diosmin, often found in combination with hesperidin, is a semisynthetic flavonoid used primarily for the treatment of chronic venous insufficiency, hemorrhoids, and related vascular disorders. It is thought to improve venous tone, lymphatic drainage, and reduce inflammation. Diosmin combinations are approved and widely used, especially in Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for diosmin, combinations (most commonly in combination with hesperidin), reported in healthy adult volunteers (mixed sex, age 18-55). PK parameters mostly refer to the major active metabolite, diosmetin, after oral administration.</p><h4>References</h4><ol><li><p>Gerges, SH, et al., &amp; El-Demerdash, E (2022). Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. <i>European journal of drug metabolism and pharmacokinetics</i> 47(1) 1–18. DOI:<a href=\"https://doi.org/10.1007/s13318-021-00731-y\">10.1007/s13318-021-00731-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34687440/\">https://pubmed.ncbi.nlm.nih.gov/34687440</a></p></li><li><p>Bedada, SK, &amp; Neerati, P (2018). Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats. <i>Naunyn-Schmiedeberg&#x27;s archives of pharmacology</i> 391(2) 115–121. DOI:<a href=\"https://doi.org/10.1007/s00210-017-1439-3\">10.1007/s00210-017-1439-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29134244/\">https://pubmed.ncbi.nlm.nih.gov/29134244</a></p></li><li><p>Bhattacharyya, S, et al., &amp; Chattopadhyay, N (2019). A nutraceutical composition containing diosmin and hesperidin has osteogenic and anti-resorptive effects and expands the anabolic window of teriparatide. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 118 109207–None. DOI:<a href=\"https://doi.org/10.1016/j.biopha.2019.109207\">10.1016/j.biopha.2019.109207</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31306971/\">https://pubmed.ncbi.nlm.nih.gov/31306971</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DiosminCombinations;
